William Blair Has Bearish Forecast for Merus Q3 Earnings

Merus (NASDAQ:MRUS) – Equities researchers at William Blair reduced their Q3 2025 EPS estimates for Merus in a research report issued on Monday, December 2nd. William Blair analyst M. Phipps now forecasts that the biotechnology company will earn ($1.00) per share for the quarter, down from their previous forecast of ($0.99). The consensus estimate for Merus’ current full-year earnings is ($3.89) per share. William Blair also issued estimates for Merus’ Q4 2025 earnings at ($1.01) EPS, FY2025 earnings at ($4.12) EPS, FY2026 earnings at ($3.97) EPS and FY2027 earnings at ($4.02) EPS.

Several other brokerages have also issued reports on MRUS. UBS Group assumed coverage on Merus in a report on Thursday, October 24th. They set a “buy” rating and a $72.00 price objective for the company. The Goldman Sachs Group began coverage on shares of Merus in a research report on Thursday, November 21st. They set a “buy” rating and a $73.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and set a $85.00 price target on shares of Merus in a report on Monday. Guggenheim restated a “buy” rating and set a $109.00 target price (down from $111.00) on shares of Merus in a report on Tuesday. Finally, HC Wainwright reissued a “buy” rating and issued a $85.00 price objective on shares of Merus in a research note on Monday. One investment analyst has rated the stock with a sell rating, twelve have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $85.27.

Merus Stock Down 1.6 %

MRUS opened at $45.49 on Wednesday. The stock has a fifty day moving average of $49.86 and a 200-day moving average of $51.85. The firm has a market capitalization of $3.11 billion, a P/E ratio of -11.52 and a beta of 1.07. Merus has a 12-month low of $22.27 and a 12-month high of $61.61.

Merus (NASDAQ:MRUS) last posted its quarterly earnings data on Thursday, October 31st. The biotechnology company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.05). The firm had revenue of $11.77 million for the quarter, compared to analysts’ expectations of $9.11 million. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in MRUS. nVerses Capital LLC raised its holdings in Merus by 750.0% in the 3rd quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 1,500 shares during the period. US Bancorp DE acquired a new position in Merus in the 3rd quarter valued at approximately $103,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Merus by 24.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 489 shares during the period. Farallon Capital Management LLC acquired a new stake in Merus during the 2nd quarter valued at approximately $237,000. Finally, ProShare Advisors LLC acquired a new stake in Merus during the 2nd quarter worth about $242,000. Institutional investors and hedge funds own 96.14% of the company’s stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.